The Archive · 3 posts
Discover Sareum Holdings PLC (SAR) - pioneering biotech innovations in cancer therapy. Explore breakthrough treatments powering your investment. 🌟
Sareum restarts Phase 2 toxicology for SDC-1801, de-risking lead psoriasis drug and confirming one-year cash runway.
March 12, 2026
Showing 2 of 3 posts
Sareum's 2025 update: SDC-1801 Phase 1 success clouded by toxicology study halt. Delay manageable with strong science backing.
JoshuaOctober 23, 2025
Sareum teams with Receptor.AI to fast-track brain-penetrating neuroinflammatory drug discovery using AI. Retains full IP ownership.
JoshuaAugust 12, 2025